Compare Crispr Therapeutics AG (CRSP) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Rocket Lab USA Inc — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while Rocket Lab USA Inc trades at $80.83 (market cap $50.01B). The key difference: Rocket Lab USA Inc is far larger — about 9.6× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| CRSP | RKLB | |
|---|---|---|
Market Cap | $5.23B | $50.01B |
Sector | Health | Technology |
52-Week High | $76.78 | $150.23 |
52-Week Low | $44.34 | $39.48 |
Enterprise Value | $3.65B | $47.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Rocket Lab (RKLB) trades at $81.17, up 1.41% today, showing strong momentum with a bullish technical outlook. The company reported record Q2 2026 revenue of $601.8M but missed EPS expectations, while maintaining a massive $2.36B backlog. Analysts remain overwhelmingly bullish with a $118 consensus target, though valuation metrics appear stretched with a P/S ratio of 60.8.
The stock offers significant upside potential driven by Neutron rocket development and growing space industry demand, but faces execution risks including margin pressures and cash burn. Near-term catalysts include the Neutron launch timeline and Iridium acquisition, though high valuation multiples require flawless execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
